Your Source for Venture Capital and Private Equity Financings

Massinvestor/VC News Daily

Atomwise Receives a $2.3M Grant

2020-10-06
SAN FRANCISCO, CA, Atomwise announced today $2.3M in grant funding for AI-based discovery of antimalarial and anti-tuberculosis therapies.
Atomwise, the leader in using artificial intelligence (AI) for small molecule drug discovery, announced today $2.3M in grant funding for AI-based discovery of antimalarial and anti-tuberculosis therapies from the Bill & Melinda Gates Foundation. The grant funding will be used to discover novel compounds that can advance the development of novel antimalarial and anti-tuberculosis small molecule therapies in collaboration with the Gates Foundation's global network of partners and funded investigators. Atomwise will provide AI-based drug discovery support to leading researchers to translate their biological discoveries into novel therapies.

Atomwise is revolutionizing how drugs are discovered with AI. We invented the use of deep learning for structure-based drug discovery, today developing a pipeline of small-molecule drug candidates advancing into preclinical studies. Our AtomNetĀ® technology has been used to unlock more undruggable targets than any other AI drug discovery platform. We are tackling over 600 unique disease targets across 775 collaborations spanning more than 250 partners around the world. Our portfolio of joint ventures and partnerships with leading pharmaceutical, agrochemical, and emerging biotechnology companies represents a collective deal value approaching $7 billion. Atomwise has raised over $174 million from leading venture capital firms to advance our mission to make better medicines, faster. Learn more at atomwise.com or follow @AtomwiseInc.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000 startups and 5,000 VC investors